AU2006305769B2 - Salts of modulators of PPAR and methods of treating metabolic disorders - Google Patents

Salts of modulators of PPAR and methods of treating metabolic disorders Download PDF

Info

Publication number
AU2006305769B2
AU2006305769B2 AU2006305769A AU2006305769A AU2006305769B2 AU 2006305769 B2 AU2006305769 B2 AU 2006305769B2 AU 2006305769 A AU2006305769 A AU 2006305769A AU 2006305769 A AU2006305769 A AU 2006305769A AU 2006305769 B2 AU2006305769 B2 AU 2006305769B2
Authority
AU
Australia
Prior art keywords
ppar
recited
group
salt
term
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006305769A
Other languages
English (en)
Other versions
AU2006305769A1 (en
Inventor
David T. Jonaitis
Stephan D. Parent
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kalypsys Inc
Original Assignee
Kalypsys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalypsys Inc filed Critical Kalypsys Inc
Publication of AU2006305769A1 publication Critical patent/AU2006305769A1/en
Application granted granted Critical
Publication of AU2006305769B2 publication Critical patent/AU2006305769B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2006305769A 2005-10-25 2006-10-23 Salts of modulators of PPAR and methods of treating metabolic disorders Ceased AU2006305769B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73024905P 2005-10-25 2005-10-25
US60/730,249 2005-10-25
PCT/US2006/060172 WO2007051095A1 (en) 2005-10-25 2006-10-23 Salts of modulators of ppar and methods of treating metabolic disorders

Publications (2)

Publication Number Publication Date
AU2006305769A1 AU2006305769A1 (en) 2007-05-03
AU2006305769B2 true AU2006305769B2 (en) 2012-06-14

Family

ID=37770916

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006305769A Ceased AU2006305769B2 (en) 2005-10-25 2006-10-23 Salts of modulators of PPAR and methods of treating metabolic disorders

Country Status (14)

Country Link
US (1) US7863276B2 (https=)
EP (1) EP1940815B1 (https=)
JP (2) JP5322650B2 (https=)
KR (1) KR101464767B1 (https=)
CN (1) CN101331122B (https=)
AU (1) AU2006305769B2 (https=)
BR (1) BRPI0619282B8 (https=)
CA (1) CA2624383C (https=)
DK (1) DK1940815T3 (https=)
ES (1) ES2691548T3 (https=)
HU (1) HUE040020T2 (https=)
IL (1) IL190396A (https=)
NZ (1) NZ566831A (https=)
WO (1) WO2007051095A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007005205A (es) * 2004-10-29 2007-05-11 Kalypsys Inc Compuestos biciclicos sulfonilo-sustituidos como moduladores de receptores activados por el proliferador de la peroxisoma.
TW200745059A (en) * 2006-05-16 2007-12-16 Kalypsys Inc Sulfonyl-substituted bicyclic compounds as modulators of PPAR
US20080004281A1 (en) * 2006-06-28 2008-01-03 Kalypsys, Inc. Methods for the modulation of crp by the selective modulation of ppar delta
WO2008091863A1 (en) * 2007-01-23 2008-07-31 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis
WO2021046081A1 (en) * 2019-09-05 2021-03-11 Rush University Medical Center Methods and compositions for treatment of demyelinating disorders

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237130A (en) * 1979-06-21 1980-12-02 Merck & Co., Inc. 2,3-Dihydro-6,7-disubstituted-5-(substituted sulfonyl)benzofuran-2-carboxylic acids
EP0173899A2 (en) * 1984-09-05 1986-03-12 Shionogi & Co., Ltd. 2,3-Dihydrobenzofuran-5-sulfonamide derivatives
US4600709A (en) * 1982-10-22 1986-07-15 Ciba-Geigy Ag Benzodioxole derivatives, processes for the manufacture thereof and corresponding pharmaceutical compositions
EP1236719A1 (en) * 1999-12-03 2002-09-04 Kyoto Pharmaceutical Industries, Ltd. Novel heterocyclic compounds and salts thereof and medicinal use of the same
CA2534171A1 (en) * 2003-08-02 2005-02-24 Bayer Healthcare Ag Bicyclic indoline sulfonamide derivatives
WO2006055187A1 (en) * 2004-10-29 2006-05-26 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as modulators of ppar

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3374408D1 (en) * 1982-10-22 1987-12-17 Ciba Geigy Ag Benzodioxole derivatives, process for their preparation and pharmaceutical compositions containing them
EP0158596A3 (de) * 1984-04-06 1986-08-13 Ciba-Geigy Ag Neue substituierte Benzodioxolderivate, Verfahren zu deren Herstellung und entsprechende pharmazeutische Zusammensetzungen
CN1014148B (zh) * 1984-09-05 1991-10-02 盐野义制药株式会社 2，3-二氢苯并呋喃-5-磺酰胺衍生物的制备方法
JPH05255089A (ja) 1991-12-18 1993-10-05 Sanwa Kagaku Kenkyusho Co Ltd 抗ウイルス剤
US5464788A (en) 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
PE86199A1 (es) 1997-06-17 1999-09-24 Schering Corp Sulfonamida inhibidor de la enzima farnesilo transferasa
TR200002182T2 (tr) 1998-01-27 2000-12-21 Aventis Pharmaceuticals Products Inc. İkame edilmiş aksozaherosayklil faktör xa inhibitörleri
US7517884B2 (en) * 1998-03-30 2009-04-14 Kalypsys Inc. Sulfonyl-substituted bicyclic compounds as modulators of PPAR
CA2342251A1 (en) 1998-08-28 2000-03-09 Scios Inc. Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase
ES2300151T3 (es) 1998-09-22 2008-06-01 Astellas Pharma Inc. Derivados de cianofenilo.
WO2000056704A1 (en) 1999-03-22 2000-09-28 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives
JP2001261657A (ja) 2000-03-17 2001-09-26 Yamanouchi Pharmaceut Co Ltd シアノフェニル誘導体
GB0007907D0 (en) 2000-03-31 2000-05-17 Merck Sharp & Dohme Therapeutic agents
CA2423744C (en) 2000-09-29 2012-04-03 Prolifix Limited Hydroxamic acid compounds comprising a sulfonamide linkage as hdac inhibitors
WO2002051836A1 (en) 2000-12-27 2002-07-04 Kyowa Hakko Kogyo Co., Ltd. Dipeptidyl peptidase iv inhibitor
IL158590A0 (en) 2001-06-11 2004-05-12 Biovitrum Ab Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes
US7456184B2 (en) 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
CA2479906C (en) 2002-04-03 2011-02-08 Topotarget Uk Limited Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
CN1181065C (zh) 2002-05-08 2004-12-22 上海医药工业研究院 芳烷甲酰烷基哌嗪衍生物及其作为脑神经保护剂的应用
EP1511488B1 (en) 2002-06-12 2013-05-22 Symphony Evolution, Inc. Human adam-10 inhibitors
CN1751037A (zh) 2003-02-14 2006-03-22 伊莱利利公司 作为ppar调节剂的磺酰胺衍生物
CA2521175A1 (en) 2003-04-07 2004-10-28 Kalypsys, Inc. Para-sulfonyl substituted phenyl compounds as modulators of ppars
US20070208026A1 (en) 2003-04-07 2007-09-06 Liu Kevin N-Containing Heteroaromatic Compounds As Modulators Of Ppars And Methods Of Treating Metabolic Disorders
KR100762762B1 (ko) 2003-04-17 2007-10-17 칼립시스, 인코포레이티드 Ｐｐａｒ의 조절인자로서의 아릴 화합물 및 신진대사장애의 치료 방법
MXPA06001202A (es) 2003-07-29 2006-08-31 Xenon Pharmaceuticals Inc Derivados piridilo y su uso como agentes terapeuticos.
KR20060036106A (ko) 2003-07-30 2006-04-27 제논 파마슈티칼스 인크. 피리딜 유도체 및 그의 치료제로서의 용도
CN1829701A (zh) 2003-07-30 2006-09-06 泽农医药公司 哌嗪衍生物和它们作为治疗剂的用途
CN101712653A (zh) 2003-07-30 2010-05-26 泽农医药公司 哒嗪衍生物和它们作为治疗剂的用途
US20050124625A1 (en) 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
WO2005060958A1 (en) 2003-12-19 2005-07-07 Kalypsys, Inc. (5- (2-phenyl)-thiazol-5-ylmethoxy)-indol-1-yl) -acetic acid derivatives and related compounds as modulators of the human ppar-delta receptor for the treatment of metabolic disorders such as type 2 diabetes
AR048523A1 (es) 2004-04-07 2006-05-03 Kalypsys Inc Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos
CA2573198A1 (en) 2004-07-06 2006-02-09 Xenon Pharmaceuticals Inc. Nicotinamide derivatives and their use as therapeutic agents
JP5080256B2 (ja) 2004-09-20 2012-11-21 ゼノン・ファーマシューティカルズ・インコーポレイテッド 二環式複素環誘導体およびステアロイル−ＣｏＡデサチュラーゼ（ＳＣＤ）のインヒビターとしてのそれらの使用
AU2005286648A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
US7829712B2 (en) 2004-09-20 2010-11-09 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
AR051091A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
EP2289510A1 (en) 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
EP1807085B1 (en) 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
CA2580762A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
EP1827438B2 (en) 2004-09-20 2014-12-10 Xenon Pharmaceuticals Inc. Piperazin derivatives for inhibiting human stearoyl-coa-desaturase
US20070190079A1 (en) 2004-10-29 2007-08-16 Kalypsys, Inc. Methods for the selective modulation of ppar
WO2007047432A1 (en) 2005-10-12 2007-04-26 Kalypsys, Inc. Sulfonamide derivatives as modulators of ppar
US20090143396A1 (en) 2005-10-12 2009-06-04 Malecha James W Sulfonyl-Substituted Aryl Compounds as Modulators of Peroxisome Proliferator Activated Receptors
EP1996198A1 (en) 2006-03-17 2008-12-03 Kalypsys, Inc. Alkylamine-substituted bicyclic aryl compounds useful as modulators of ppar
US20070249519A1 (en) 2006-04-20 2007-10-25 Kalypsys, Inc. Methods for the upregulation of glut4 via modulation of ppar delta in adipose tissue and for the treatment of disease
US20080004281A1 (en) 2006-06-28 2008-01-03 Kalypsys, Inc. Methods for the modulation of crp by the selective modulation of ppar delta
WO2008043024A2 (en) 2006-10-04 2008-04-10 Kalypsys, Inc. Oral pharmaceutical formulation comprising a sulfonyl bicyclic modulator of ppar for the treatment of disease
US20080287477A1 (en) 2006-10-11 2008-11-20 Kalypsys, Inc. Novel Compounds as Modulators of Ppar
WO2008091863A1 (en) 2007-01-23 2008-07-31 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237130A (en) * 1979-06-21 1980-12-02 Merck & Co., Inc. 2,3-Dihydro-6,7-disubstituted-5-(substituted sulfonyl)benzofuran-2-carboxylic acids
US4600709A (en) * 1982-10-22 1986-07-15 Ciba-Geigy Ag Benzodioxole derivatives, processes for the manufacture thereof and corresponding pharmaceutical compositions
EP0173899A2 (en) * 1984-09-05 1986-03-12 Shionogi & Co., Ltd. 2,3-Dihydrobenzofuran-5-sulfonamide derivatives
EP1236719A1 (en) * 1999-12-03 2002-09-04 Kyoto Pharmaceutical Industries, Ltd. Novel heterocyclic compounds and salts thereof and medicinal use of the same
CA2534171A1 (en) * 2003-08-02 2005-02-24 Bayer Healthcare Ag Bicyclic indoline sulfonamide derivatives
WO2006055187A1 (en) * 2004-10-29 2006-05-26 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as modulators of ppar

Also Published As

Publication number Publication date
CN101331122B (zh) 2011-09-07
BRPI0619282A2 (pt) 2011-09-20
NZ566831A (en) 2011-09-30
ES2691548T3 (es) 2018-11-27
EP1940815B1 (en) 2018-08-15
WO2007051095A1 (en) 2007-05-03
JP5322650B2 (ja) 2013-10-23
DK1940815T3 (en) 2018-11-05
KR20080059575A (ko) 2008-06-30
IL190396A0 (en) 2008-11-03
EP1940815A1 (en) 2008-07-09
KR101464767B1 (ko) 2014-11-24
IL190396A (en) 2017-09-28
US20070093504A1 (en) 2007-04-26
BRPI0619282B1 (pt) 2021-05-04
CN101331122A (zh) 2008-12-24
JP2009513679A (ja) 2009-04-02
JP2013166788A (ja) 2013-08-29
CA2624383C (en) 2014-03-11
HUE040020T2 (hu) 2019-02-28
US7863276B2 (en) 2011-01-04
BRPI0619282B8 (pt) 2021-05-25
AU2006305769A1 (en) 2007-05-03
CA2624383A1 (en) 2007-05-03

Similar Documents

Publication Publication Date Title
KR0174752B1 (ko) 이환식 헤테로환 함유 술폰아미드 유도체 및 그 제조방법
AU2005307006B2 (en) Sulfonyl-substituted bicyclic compounds as modulators of PPAR
AU2011239966B2 (en) Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
JP2022529615A (ja) Ｍａｓ関連ｇタンパク質受容体ｘ４のモジュレーターおよび関連製品ならびに方法
WO2003074525A1 (fr) Compose heterocyclique azote
JP2012514038A (ja) 嚢胞性線維症膜コンダクタンス調節因子のモジュレーター
JP6811233B2 (ja) Ｔｎｆアルファの修飾因子として有用な環状化合物
EP3271362B1 (en) Heterocyclic compounds useful as inhibitors of tnf
WO2018013772A1 (en) Monocyclic heteroaryl substituted compounds
CA2911693A1 (en) 4-amino-6-phenyl-6,7-dihydro[1,2,3]triazolo[1,5-a]pyrazine derivatives as inhibitors of beta-secretase (bace)
WO2007137098A2 (en) Sulfonyl-substituted bicyclic compounds as modulators of ppar
JP2013166788A (ja) Ｐｐａｒ調節剤の塩および代謝障害の治療方法
EP1996198A1 (en) Alkylamine-substituted bicyclic aryl compounds useful as modulators of ppar
JP2023518299A (ja) 小分子エナンチオマーによるアンドロゲン受容体調節
WO2007047431A2 (en) Sulfonyl-substituted aryl compounds as modulators of peroxisome proliferator activated receptors
US20080287477A1 (en) Novel Compounds as Modulators of Ppar
WO2007047432A1 (en) Sulfonamide derivatives as modulators of ppar
TWI386392B (zh) 一種可作為過氧小體增生活化受體調控劑的磺酸基取代雙環化合物
CN101421258B (zh) 作为ppar调节剂的磺酰基取代的双环化合物
HK1143363A (en) Modulators of cystic fibrosis transmembrane conductance regulator
HK1143363B (en) Modulators of cystic fibrosis transmembrane conductance regulator
HK1139666B (en) Modulators of cystic fibrosis transmembrane conductance regulator
HK1139666A1 (en) Modulators of cystic fibrosis transmembrane conductance regulator

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired